Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 6,838,000 | 3,860,000 | 3,844,000 | 9,407,000 | 18,620,000 |
| Marketable Securities | 310,000 | 280,000 | 242,000 | 203,000 | 155,000 |
| Receivables | 6,414,000 | 5,425,000 | 5,182,000 | 5,249,000 | 3,248,000 |
| Inventories | 5,012,000 | 4,316,000 | 3,796,000 | 3,601,000 | 2,434,000 |
| Other current assets | 0 | 0 | 0 | 20,000 | 513,000 |
| TOTAL | $20,441,000 | $15,667,000 | $14,632,000 | $20,147,000 | $26,776,000 |
| Non-Current Assets | |||||
| PPE Net | 9,029,000 | 8,038,000 | 7,563,000 | 7,607,000 | 5,705,000 |
| Investments And Advances | 821,000 | 883,000 | 897,000 | 883,000 | 2,947,000 |
| Intangibles | 38,528,000 | 40,220,000 | 42,196,000 | 45,493,000 | 12,222,000 |
| Other Non-Current Assets | 3,729,000 | 3,079,000 | 1,885,000 | 2,120,000 | 5,016,000 |
| TOTAL | $52,107,000 | $52,220,000 | $52,541,000 | $56,103,000 | $25,890,000 |
| Total Assets | $72,548,000 | $67,887,000 | $67,173,000 | $76,250,000 | $52,666,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 7,000 | 1,277,000 | 7,000 | 508,000 | 3,000 |
| Accounts payable and accrued liabilities | 3,946,000 | 3,252,000 | 2,975,000 | 2,402,000 | 1,178,000 |
| Accrued Expenses | 1,416,000 | 1,237,000 | 1,182,000 | 1,187,000 | 752,000 |
| Other current liabilities | N/A | N/A | N/A | N/A | 245,000 |
| TOTAL | $11,907,000 | $10,863,000 | $9,012,000 | $8,912,000 | $6,660,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 18,527,000 | 16,661,000 | 19,359,000 | 27,210,000 | 20,681,000 |
| Other Non-Current Liabilities | 9,111,000 | 9,062,000 | 8,080,000 | 9,030,000 | 4,608,000 |
| TOTAL | $27,638,000 | $25,723,000 | $27,439,000 | $36,240,000 | $25,289,000 |
| Total Liabilities | $39,545,000 | $36,586,000 | $36,451,000 | $45,152,000 | $31,949,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,771,529 | 1,763,433 | 1,756,470 | 1,746,334 | 1,727,998 |
| Common Shares | 24,145,000 | 23,853,000 | 23,512,000 | 23,206,000 | 13,027,000 |
| Retained earnings | 27,627,000 | 25,847,000 | 24,560,000 | 23,978,000 | 25,565,000 |
| Other shareholders' equity | -8,727,000 | -8,252,000 | -7,388,000 | -5,861,000 | -7,084,000 |
| TOTAL | $33,003,000 | $31,301,000 | $30,722,000 | $31,098,000 | $20,717,000 |
| Total Liabilities And Equity | $72,548,000 | $67,887,000 | $67,173,000 | $76,250,000 | $52,666,000 |